Mellon has established a Supervisory Board to provide the necessary guidance to realize its vision: to improve medical procedures by offering the best possible tools.
Jan Hendrik Egberts
Jan has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as CEO at Agendia Inc., a molecular diagnostics company. Prior to this, he was CEO of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013. Jan also served as a senior healthcare advisor for 3i Group plc, a private equity firm and as President, Chairman and CEO of NovaDel Pharmaceuticals Inc., where he developed a portfolio of pre-clinical and clinical compounds, gaining FDA approval for two compounds. In addition, Jan has held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care. He graduated from Erasmus University Medical School in the Netherlands and he obtained his MBA from Stanford after which he worked as a management consultant for McKinsey & Co. Jan continues to serve on the supervisory board of CHDR (Center for Human Drug Research), Pharming Group N.V., LeadPharma and Implanet S.A.